

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1145642
<b>Application Number:</b>	10597792
<b>Confirmation Number:</b>	6405
<b>Title of Invention:</b>	2-Methoxy-5(5-Trifluoromethyl-Tetrazol-1-YL-Benzyl)-2S-Phenyl-Piperidin-3S-YL)-Amine For The Treatment of Social Phobia
<b>First Named Inventor:</b>	Massimo Bani
<b>Customer Number:</b>	23347
<b>Filer:</b>	Lorie Ann Morgan/Valerie Phillips
<b>Filer Authorized By:</b>	Lorie Ann Morgan
<b>Attorney Docket Number:</b>	PB60734USW
<b>Receipt Date:</b>	08-AUG-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	14:46:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	PCT/EP05/01441

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$900
RAM confirmation Number	14
Deposit Account	071392
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Transmittal letter	PB60734USWtransmittalLetter.pdf	69843	no	3
<b>Warnings:</b>					
<b>Information:</b>					
2	Documents submitted with 371 Applications	PB60734USWisr.pdf	175634	no	7
<b>Warnings:</b>					
<b>Information:</b>					
3	Documents submitted with 371 Applications	PB60734USWwrittenOpinion.pdf	124775	no	6
<b>Warnings:</b>					
<b>Information:</b>					
4	Documents submitted with 371 Applications	PB60734USWpctlB371.pdf	38940	no	1
<b>Warnings:</b>					
<b>Information:</b>					
5	Information Disclosure Statement (IDS) Filed	PB60734USWidsandpto1449.pdf	51049	no	3
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
6	Foreign Reference	WO9508549.pdf	3681685	no	94
<b>Warnings:</b>					
<b>Information:</b>					
7		PB60734USWPrelimAmend.pdf	44806	yes	5
	<b>Multipart Description</b>				
	<b>Doc Desc</b>		<b>Start</b>	<b>End</b>	
	Preliminary Amendment		1	2	
	Claims		3	3	
	Applicant Arguments/Remarks Made in an Amendment		4	4	

	Abstract		5	5
<b>Warnings:</b>				
<b>Information:</b>				
8	Documents submitted with 371 Applications	PB60734USWPCTCoverPage.pdf	42246	no 1
<b>Warnings:</b>				
<b>Information:</b>				
9	Documents submitted with 371 Applications	Pb60734USWPCTRequest.pdf	47052	no 3
<b>Warnings:</b>				
<b>Information:</b>				
10	Documents submitted with 371 Applications	PB60734USWPOAstatement ResolutionAssignment.pdf	165173	no 7
<b>Warnings:</b>				
<b>Information:</b>				
11	Fee Worksheet (PTO-875)	fee-info.pdf	8464	no 2
<b>Warnings:</b>				
<b>Information:</b>				
<b>Total Files Size (in bytes):</b>			4449667	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>				